📊 RNTX Key Takeaways
Is Rein Therapeutics, Inc. (RNTX) a Good Investment?
Rein Therapeutics is a pre-revenue pharmaceutical company facing an acute financial crisis with only ~12-18 months of cash runway ($4.4M cash against $3.6M annual cash burn) and severely impaired liquidity (0.40x current ratio). The company burns $3.4M in operating cash flow annually with zero revenue, and current liabilities exceed current assets by 2.5x, indicating imminent insolvency without capital infusion.
Pre-revenue with large operating losses and very weak liquidity (current ratio 0.70x; $3.21M cash vs ~$19.4M annual operating cash outflow) signal a near-term funding gap. While debt-free and capex-light, severely negative ROE/ROA and persistent burn imply high dilution or going-concern risk absent timely non-dilutive funding or commercialization.
Why Buy Rein Therapeutics, Inc. Stock? RNTX Key Strengths
- Minimal debt burden with no long-term debt obligation
- Positive stockholders equity of $11.6M provides some asset cushion
- Limited insider selling activity suggests limited insider concern about immediate collapse
- Debt-free balance sheet (Debt/Equity 0.00x) with no interest burden
- Capex-light profile ($157k) preserving flexibility
- EPS loss improved YoY (+44.2%) despite flat net loss
RNTX Stock Risks: Rein Therapeutics, Inc. Investment Risks
- Zero revenue with no commercialized products or clear path to revenue
- Critical cash runway of 12-18 months at current burn rate before insolvency
- Severe liquidity crisis: 0.40x current ratio means liabilities exceed liquid assets by 2.5x, unable to meet short-term obligations
- Negative operating cash flow of -$3.4M annually indicates core R&D operations are not self-sustaining
- Highly dilutive capital raise likely required within 12 months, destroying shareholder value
- Liquidity shortfall and limited runway (current ratio 0.70x; cash $3.21M)
- Sustained operating and cash flow losses (Op income -$50.63M; OCF -$19.36M)
- High dilution or going-concern risk due to external financing needs
Key Metrics to Watch
- Monthly cash burn rate and remaining runway (urgency of capital needs)
- Product development milestones and clinical trial progress toward revenue
- Equity raise activity and dilution impact on existing shareholders
- Operating cash flow (burn rate)
- Cash & equivalents
Rein Therapeutics, Inc. (RNTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
RNTX Profit Margin, ROE & Profitability Analysis
RNTX vs Healthcare Sector: How Rein Therapeutics, Inc. Compares
How Rein Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rein Therapeutics, Inc. Stock Overvalued? RNTX Valuation Analysis 2026
Based on fundamental analysis, Rein Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rein Therapeutics, Inc. Balance Sheet: RNTX Debt, Cash & Liquidity
RNTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rein Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.51 indicates the company is currently unprofitable.
RNTX Revenue Growth, EPS Growth & YoY Performance
RNTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$5.5M | $-0.19 |
| Q3 2025 | N/A | -$5.5M | $-0.21 |
| Q2 2025 | N/A | -$5.5M | $-0.28 |
| Q1 2025 | N/A | -$5.5M | $-0.25 |
| Q3 2024 | N/A | -$1.8M | $-0.27 |
| Q2 2024 | N/A | -$1.8M | $-0.39 |
| Q1 2024 | N/A | -$4.8M | $-0.86 |
| Q3 2023 | N/A | -$1.8M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rein Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
RNTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rein Therapeutics, Inc. (CIK: 0001420565)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RNTX
What is the AI rating for RNTX?
Rein Therapeutics, Inc. (RNTX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RNTX's key strengths?
Claude: Minimal debt burden with no long-term debt obligation. Positive stockholders equity of $11.6M provides some asset cushion. ChatGPT: Debt-free balance sheet (Debt/Equity 0.00x) with no interest burden. Capex-light profile ($157k) preserving flexibility.
What are the risks of investing in RNTX?
Claude: Zero revenue with no commercialized products or clear path to revenue. Critical cash runway of 12-18 months at current burn rate before insolvency. ChatGPT: Liquidity shortfall and limited runway (current ratio 0.70x; cash $3.21M). Sustained operating and cash flow losses (Op income -$50.63M; OCF -$19.36M).
What is RNTX's revenue and growth?
Rein Therapeutics, Inc. reported revenue of $0.0.
Does RNTX pay dividends?
Rein Therapeutics, Inc. does not currently pay dividends.
Where can I find RNTX SEC filings?
Official SEC filings for Rein Therapeutics, Inc. (CIK: 0001420565) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RNTX's EPS?
Rein Therapeutics, Inc. has a diluted EPS of $-0.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RNTX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Rein Therapeutics, Inc. has a STRONG SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RNTX stock overvalued or undervalued?
Valuation metrics for RNTX: ROE of -50.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RNTX stock in 2026?
Our dual AI analysis gives Rein Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RNTX's free cash flow?
Rein Therapeutics, Inc.'s operating cash flow is $-3.4M, with capital expenditures of $157.0K.
How does RNTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -50.4% (avg: 15%), current ratio 0.40 (avg: 2).